AstraZeneca stock targets the weight loss market with three drugs

Published on 10/07/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock is building a three-drug weight loss pipeline on October 7, 2026. Q2 revenue reached USD 15.38 billion, up 6.4 percent year over year.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und Impfstofffläschchen — AstraZeneca plc (ISIN GB0009895292) ist als forschendes Pharmaunternehmen an internationalen Börsen wie London gelistet, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) was trading at GBp 12,046 on the LSE on October 7, 2026, at 12:40 p.m. London time, up 0.74 percent from the previous close. The company is targeting the weight loss market with three drug candidates, including a daily pill, as MedWatch reported on October 7, 2026.

Three drugs enter weight loss race

The pipeline includes elecoglipron, an asset AstraZeneca acquired from Eccogene in 2023. The daily-pill angle matters because oral treatment could widen access beyond injectable therapies, while the company faces established competition from Novo Nordisk and Eli Lilly, according to MedWatch.

The addressable market cited in the report could reach USD 100 billion in annual sales by 2030. That figure describes the industry opportunity, not AstraZeneca revenue, so the investment case still depends on clinical progress and commercial execution.

Q2 revenue rose 6.4 percent

AstraZeneca released Q2 2026 results on July 27, 2026, with revenue of USD 15.38 billion, up 6.4 percent from the prior year. According to MarketBeat, reported EPS was USD 2.63 against a USD 2.50 consensus, a USD 0.13 beat, while revenue was below the USD 15.44 billion estimate.

The contrast gives investors two separate signals: operating scale continued to expand, but sales came in USD 60 million below consensus. AstraZeneca's future growth therefore rests on both established medicines and new launches such as the weight loss candidates.

Analysts keep a positive stance

MarketBeat reported on October 7, 2026, that Berenberg reaffirmed a Buy rating and a GBP 175.00 price target. The same report said six analysts had Buy ratings and one had a Hold rating, producing a Moderate Buy consensus with an average target of GBP 153.57.

AstraZeneca's investor-relations calendar lists a Meet the Management event for October 12, 2026, at ASBMR and another for October 26, 2026, at ESMO. The dates give investors two near-term checkpoints for pipeline commentary, while the next quarterly report remains the more important test of revenue momentum.

Stock stays within yearly range

AstraZeneca's LSE share price was GBp 12,046 on October 7, 2026, with a session low of GBp 11,894 and a high of GBp 12,046. The 52-week range was GBp 9,892 to GBp 15,732, placing the stock below its yearly high while the current pipeline story develops.